Kornimate/medical-research-clean huggingface dataset:
defining the optimal location to place an adductor canal block

Conditions: Knee Arthropathy

Summary: the aim of the current project is to address a gap in the existing literature related to optimal placement of local anesthetic for an adductor canal (ac) block. the current study seeks to examine whether placement of the local anesthetic in the ac for knee surgery is more effective at reducing post-operative pain following arthroscopic knee surgery compared to a control. specifically, if the anesthetic is more beneficial than the control group, the research will determine which location is optimal by comparing groups that receive anesthetic in the midpoint of the thigh, the proximal end of the thigh, or the distal end of the thigh.

although there has been an abundance of literature highlighting the efficacy of using regional blocks to decrease post-operative pain, the exact location of placement of local anesthetic for anesthetizing the nerves in the ac is unknown for optimal pain relief in patients undergoing knee surgery. the saphenous nerve consistently lies in the ac at various points of local anesthetic deposit, however there are many other nerves that lie in the canal that may branch off proximally or distally from the ac that are important to target in achieving optimal pain relief for patients undergoing knee arthroscopy.1-3 the ac is bounded in a triangular shape by the vastus medialis anterolaterally, the sartorius medially, and the adductor longus/adductor magnus posteriorly. the canal contains the deep femoral artery and the deep femoral vein. the saphenous nerve consistently lies within this canal, a significant sensory contributor to the knee.1-3 other branches of the femoral nerve can also be found in the ac. the nerve to the vastus medialis (nvm) and the posterior branches of the obtruator nerve (pon) can also be found, although inconsistently, in the ac at various locations.4,5 these nerves are thought to innervate the knee as well and contribute to pain when missed during this block. the course of these nerves is unknown. while some surmise that the nvm branches proximally and the pon branches distally, there is no consensus on this. currently, an ac block is most often placed in the mid-thigh as measured by visual observation. the investigators seek to investigate where along the tract of the ac would be optimal to place local anesthetic to optimize analgesia on all nerves that innervate the knee without having motor loss as would occur with a femoral nerve block

Eligibility criteria:
inclusion criteria: * patient is 7 to ≤ 17 years of age * patient at st. christopher's hospital for children * receiving a knee arthroscopy procedure * english speaking exclusion criteria: * patient is less than 7 years of age or over 17 years of age * patient has cognitive impairments * patient had previous operations on the same lower extremity as the current knee arthroscopy * patient has a positive b-hcg (identified through urine or blood test) * patient does not speak english
the effect of aromatherapy before clinical practice on stress, anxiety and depression in midwifery students

Conditions: Aromatherapy; Stress; Depression

Summary: this study was planned as a randomized controlled study to determine the effects of petitgrain and ylang ylang oil applied before clinical practice on stress, anxiety and depression in midwifery students.


Eligibility criteria:
inclusion criteria: * being a midwifery student exclusion criteria: * having an asthma or any other respiration disease * trouble of smelling * allergies to petitgrain or ylang-ylang essential oil
transcutaneous vibro-acoustic therapy in parkinson disease

Conditions: Parkinson Disease

Summary: small exploratory pilot study to assess effects of a transcutaneous vibro-acoustic therapy device (apollo neuro) in people with parkinson's disease (pd).

the overarching goal of this study is to investigate changes in anxiety, nighttime heart rate variability, and fear of falling in people with pd before and after 3-months usage of a transcutaneous vibro-acoustic therapy device. positive findings in this small exploratory pilot trial may support future studies of transcutaneous vibro-acoustic therapy for individuals with pd.

Eligibility criteria:
inclusion criteria: * diagnosed with parkinson's disease (hoehn and yahr stage 2 or higher) * individuals on or off dopaminergic therapy * present of anxiety or panic disorder * fear of falling * understanding of use and care of smart phones and devices exclusion criteria: * presence of significant dementia * disorders which may resemble pd, such as dementia with lewy bodies, vascular dementia, normal pressure hydrocephalus, multiple system atrophy, corticobasal ganglionic degeneration, or toxic causes of parkinsonism. * patients with a cardiac pacemaker * history of brain surgery or placement of a deep brain stimulator * psoriasis vulgaris (or other inflammatory skin condition) on or near skin where the vibro-acoustic device and sleep tracking ring will be donned. * patients on beta-blockers, benzodiazepines, antipsychotics, and stimulants (except for the treatment of attention deficit disorder/adhd). * pregnancy * patients who begin cognitive behavioral therapy or a selective serotonin reuptake inhibitor (ssri) medication for an anxiety disorder or other psychiatric disorder after the baseline clinical assessment.

Keywords: transcutaneous vibro-acoustic therapy anxiety
efficacy and safety of ranibizumab in two "treat and extend" treatment algorithms versus ranibizumab as needed in patients with macular edema and visual impairment secondary to diabetes mellitus

Conditions: Diabetic Macular Edema

Summary: the purpose of this study is to demonstrate that two investigational treatment regimens have the potential to result in a superior visual acuity improvement as compared to a ranibizumab pro re nata (prn=as needed) treatment regimen.


Eligibility criteria:
inclusion criteria: patient * patients with type 1 or type 2 diabetes mellitus (according to american diabetes association or world health organization \[who\] guidelines) with glycosylated hemoglobin (hba1c) ≤ 12.0% at screening (visit 1). patients should be on diet, exercise, and/or pharmacological treatment for diabetes. treatment for diabetes must have been stable for at least 3 month. ocular * patients with visual impairment due to dme in at least one eye who are eligible for laser treatment in the opinion of the investigator. if both eyes are eligible, the one with the worse visual acuity, as assessed at visit 1, will be selected by the investigator as the study eye. * bcva ≥ 39 and ≤78 letters in the study eye and, inclusively, using early treatment diabetic retinopathy study (etdrs)-like visual acuity testing charts at a testing distance of 4 meters (approximate snellen equivalent of 20/32 to 20/160) at screening. * concomitant conditions in the study eye are only permitted if, in the opinion of the investigator, they do not prevent improvement of visual acuity on study treatment. exclusion criteria: patient compliance/ administrative * pregnant or nursing (lactating) women. ocular medical history * active intraocular inflammation (grade trace or above) in either eye at enrollment. * any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye at the time of enrollment. * history of uveitis in either eye at any time. * structural damage within 0.5 disc diameter of the center of the macular in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema. * uncontrolled glaucoma in either eye at screening. prior ocular treatments * panretinal laser photocoagulation in the study eye within 6 months prior to randomization. * focal/grid laser photocoagulation in the study eye within 3 months prior to randomization. * treatment with anti-angiogenic drugs in either eye. systemic conditions or treatments * history of stroke within 6 months prior to enrollment. * renal failure requiring dialysis. * untreated diabetes mellitus. * blood pressure systolic \> 160 mmhg or diastolic \> 100 mmhg. other protocol-defined inclusion/exclusion criteria may apply

Keywords: dme diabetic macula edema retain ranibizumab
developing a new metabolic imaging approach (amri) for evaluating neurological disease in patients with gliomas

Conditions: Glioma

Summary: this is an observational study to compare the utility of the novel amri approach in human brain to the standard of care imaging approach for diagnosing and assessing glioma. tumor cells have altered metabolism compared to normal cells.this makes metabolic activity imaging useful for diagnosing and assessing neurological disease. however, current options for metabolic activity imaging are limited. metabolic activity imaging is primarily conducted using positron emission tomography (pet) with a radioactive tracer called fludeoxyglucose f-18 (¹⁸fdg). a pet scan is a procedure in which a small amount of radioactive glucose (¹⁸fdg) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. pet imaging is very expensive and is usually much less available than other imaging techniques such as magnetic resonance imaging (mri). mri uses radiofrequency waves and a strong magnetic field to provide clear and detailed pictures of internal organs and tissues. while mri is more available than pet, it isn't as useful in evaluating metabolic activity. unlike standard mri, the amri approach uses new ways of analyzing mri images that provides information about tumor cell metabolic activity. via direct comparison with a standard metabolic imaging approach, ¹⁸fdg pet, this clinical trial will assess the validity of amri as a metabolic imaging approach for evaluating neurological disease in patients with glioma.

primary objective: i. characterize how the metabolic amri parameter kᵢₒ\*v differs in tumor versus (vs) normal brain. researchers will assess the validity of amri as a metabolic imaging approach via direct comparison with a standard metabolic imaging approach, ¹⁸fdg pet. secondary objectives: i. post-gadolinium (gd) t1 mri will be used to distinguish the contrast-enhancing "ring" region indicating the metabolically active tumor periphery from the less viable and/or necrotic tumor core. the utility of amri to differentially assess the metabolically active tumor periphery and necrotic core regions will be determined and compared to that of ¹⁸fdg pet (suvmax). ii. characterize how the metabolic amri parameter kᵢₒ\*v differs in the various normal appearing brain sub-regions unaffected by tumor, in comparison to ¹⁸fdg pet. exploratory objective: i. to compare how the amri metabolic parameter kᵢₒ\*v within disease lesions change with different disease types, their disease stage, and their treatment status. outline: patients receive ¹⁸fdg iv, then 60 minutes later undergo simultaneous mri and pet scanning. during this scanning period, patients will receive gadoterate meglumine iv to obtain post-contrast mri. total scanning time will take 45-60 minutes.

Eligibility criteria:
inclusion criteria: * adult patients (greater than 18 years of age) with glioma who require mri and ¹⁸fdg-pet imaging.
a study to evaluate the pharmacokinetic profiles and safety of ckd-393(2) in healthy volunteers under fed conditions

Conditions: Type2Diabetes

Summary: a study to evaluate the pharmacokinetic profiles and safety of ckd-393(2) in healthy volunteers under fed conditions

a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of ckd-393(2) in healthy volunteers under fed conditions

Eligibility criteria:
inclusion criteria: 1. healthy adult volunteers aged 19 ≤ \~ \< 55-year-old. 2. weight ≥55kg (man) or 45kg (woman), with calculated body mass index(bmi) of 17.5 ≤ \~ \< 30.5 kg/m2. 3. those who have no congenital diseases or chronic diseases within 3 years and have no abnormal symptoms or findings. 4. those who are eligible for clinical trials based on laboratory(hematology, blood chemistry, serology, urology) and 12-lead ecg results at screening. exclusion criteria: 1. those who have clinically significant disease or medical history of heart failure, hepatopathy, type 1 diabetes, diabetic ketoacidosis, edema, renal dysfunction, galactose intolerance, glucose-galactose malabsorption. and those who receive intravenous administration of radioactive iodine contrast agents (for intravenous urography, venous cholangiography, angiography, computed tomography using contrast agents, etc.) during clinical trial. 2. those who have past medical history of gastrointestinal disorder (crohn's disease, ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect the absorption of investigational drug. 3. those who are pregnant or breastfeeding. 4. those who are deemed inappropriate to participate in clinical trial by investigators.
workshops for veterans with vision and hearing loss

Conditions: Deafness; Blindness

Summary: this is a pilot study of workshops to help veterans with both vision and hearing loss live a happier, fuller and less stressful life. the results will be used to guide the development of a large scale clinical trial.

this pilot study will enrolled 13 veterans with dual sensory loss (dsl), age 65 to over 89. the project headquarters in the portland oregon veterans affairs medical center will be tasked with the development of the workshops and writing of a curriculum and procedures manual. the atlanta vamc research collaborators enrolled the 13 veterans. staff turnover reduced time available for enrollment and data collection. we therefore eliminated the original comparison group design and this study had only one experimental intervention arm and no control intervention or other arm. veterans were chronologically enrolled who responded to recruitment letters and who passed telephone and onsite screening. the intervention consisted of six weekly two hour workshops providing information, skills training and exercises about self-managing dsl effects on daily life. preliminary effectiveness data was collected and analyzed, and a large scale clinical trial will be proposed as a followup to explore the efficacy of this management approach. this study data tracked pre and post intervention within subject changes.

Eligibility criteria:
inclusion criteria: * veteran; * vision loss \> 20/70 better eye; * hearing loss \> 40 decibels better ear; * cognition within normal limits (wnl); * no behavioral flag or psychiatric diagnosis; * documented psychosocial restrictions secondary to vision and hearing loss exclusion criteria: * vision and/or hearing can be corrected by surgical or pharmacological treatment; * requires use of sign language interpreter

Keywords: deafness-blindness pilot study self management education dual sensory loss rehabilitation peer support groups age related
systemic and white adipose tissue inflammatory profile in lean versus obese individuals

Conditions: Inflammation; Obesity; Inflammatory Response; Cardiovascular Risk Factor

Summary: this study will compare the systemic and white adipose tissue inflammatory profile of individuals who are classified as lean and obese. blood and white adipose tissue samples will be collected in the fasted state to assess inflammatory status. there is evidence to suggest that markers of inflammation in the blood and white adipose tissue increase with increasing levels of obesity. however, the white adipose tissue total protein content and phosphorylation of proteins involved in inflammatory pathways has not previously been compared between lean and obese individuals. the investigators hypothesise that obese individuals will have increased levels of inflammation in the blood and white adipose tissue, compared to their lean counterparts.


Eligibility criteria:
inclusion criteria: * 18-40 years * waist circumference/bmi criteria: * lean participants: waist circumference ≤94 cm (men) and 80 cm (women) and bmi ≥ 21.0 kg/m2 or * obese participants: waist circumference ≥102 cm (men) and 88 cm (women) and bmi ≥ 30.0kg/m2 * recreationally active (\> 3 x 30 min moderate exercise per week) * blood pressure systolic blood pressure \<160 mmhg and diastolic blood pressure \<100 mmhg exclusion criteria: * smoker (including vaping) * cardiometabolic or inflammatory disease (e.g. heart disease, high blood pressure, type 2 diabetes) * taking medication or nutritional supplements (e.g. fish oil/prebiotics) known to interfere with study outcomes (including inflammation, immune function or lipid/carbohydrate metabolism) or prescribed antibiotics within the last 3 months * unstable weight history (≥ 3kg loss or gain in previous 3 months) * an allergy to lidocaine (determined by the schools standard health questionnaire) * parallel participation in another intervention study * women who are pregnant or lactating * any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a metabolic study * alcohol consumption \>28 units per week for a man or \>21 units per week for a woman
the effect of emotional freedom techniques application on patients with cancer phobia

Conditions: Postoperative Complications; Emotion Regulation; Death Anxiety

Summary: the aim is to examine the effect of emotional freedom technique on death anxiety in patients with postoperative cancer phobia. the hypotheses of the study are as follows: h0: emotional freedom technique has no effect on postoperative death anxiety in patients with cancer phobia. h1: emotional freedom technique has a positive effect on postoperative death anxiety in patients with cancer phobia.

intervention group after coming to the clinic after surgery and after their condition was stable, the patients were given the patient introduction form, subjective discomfort unit, cancer anxiety scale and death anxiety scale as a pre-test. the researchers provided emotional freedom technique (eft) training to the patients and asked them to apply emotional freedom technique. after an average of 3 days, the subjective discomfort unit, cancer anxiety scale and death anxiety scale were applied as a post-test. control group after coming to the clinic after surgery and after their condition was stable, the patient introduction form, subjective discomfort unit, cancer anxiety scale and death anxiety scale were applied as a pre-test. no intervention was made to the control group patients outside the clinical protocol. after an average of 3 days, the subjective discomfort unit, cancer anxiety scale and death anxiety scale were applied as a post-test.

Eligibility criteria:
inclusion criteria: * being over 18 years of age, * having had oncological surgery, * having no visual or auditory problems, * having no psychiatric problems. exclusion criteria: * not accepting to participate in the study or wanting to leave, * being under 18 years of age, * having been previously diagnosed with cancer.

Keywords: death anxiety postoperative emotional freedom technique cancer phobia
efficacy of selegiline in negative symptoms of schizophrenia

Conditions: Schizophrenia

Summary: antipsychotic drugs are effective in treating the positive symptoms of schizophrenia; however their efficacy in treating negative symptoms is limited. this study wants to evaluate efficacy of selegiline augmentation of antipsychotic medication to treat negative symptoms in inpatients with chronic schizophrenia. with randomized clinical trial two groups of patients will select to receive selegiline or placebo. primary end point is decreasing in negative symptoms in case group. inclusion criteria : 1- patients with moderate to severe negative symptoms 2- patients with at least one year antipsychotic drug therapy, at the current dose \>= 1 month. 3- no other psychotropic drugs during past month. exclusion criteria: 1- severe major depressive disorder, substance abuse, severe positive symptoms of schizophrenia, treatment of mdd with antidepressant drugs during past month.


Eligibility criteria:
inclusion criteria: * patients with moderate to severe negative symptoms * patients with at least one year antipsychotic drug therapy, at the current dose \>= 1 month. * no other psychotropic drugs during past month exclusion criteria: * severe major depressive disorder * substance abuse * severe positive symptoms of schizophrenia * treatment of mdd with antidepressant drugs during past month.

Keywords: seligiline negative symptoms schizopherenia
a study evaluating the safety, pharmacokinetics, and pharmacodynamics of ka34 in subjects with knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: this study will evaluate the safety and tolerability of ka34 when administered via intra-articular injection to subjects with osteoarthritis of the knee.

this is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ka34 when administered via intra-articular injection to subjects with osteoarthritis of the knee. oa patients are randomized to receive either placebo or ka34 active drug in the range of 50-400 ug by intra-articular injection. the first portion of the study is with single ascending doses, the second portion of the study is with multiple ascending doses.

Eligibility criteria:
inclusion criteria: * diagnosis of localized osteoarthritis of the knee * males willing to use contraception and females who are no longer able to bear children exclusion criteria: * body mass index (bmi) \> 40 * grade 0, 3 or 4 osteoarthritis on the kellgren and lawrence classification system * injury to the knee or other joint within the last 12 months * receipt of any investigational product or experimental therapeutic procedure within the last 12 weeks

Keywords: osteoarthritis arthritis joint disease osteoarthritis, knee